You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动|绿叶制药涨近4%利斯的明单日透皮贴剂获德国上市批准
格隆汇 07-15 13:27
格隆汇7月15日丨绿叶制药(2186.HK)现涨3.73%,报5.84港元,暂成交3168万,最新总市值191亿港元。

公司午间公告称,集团剂量为13.3mg/24h的利斯的明单日透皮贴剂,以低剂量(4.6和9.5mg/24h)作为现有销售许可的延伸提交,获得德国药品和医疗器械管理局(BfArM)非集中审评程序(DCP)上市批准。利斯的明单日透皮贴剂已经在全球超过25个国家商业化。除利斯的明透皮贴剂外,集团还有多个中枢神经产品线的在研产品,同步开发中国及海外市场。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account